How to Come Off a GLP-1 Without Regaining the Weight

If you're thinking about stopping your GLP-1 — because of cost, side effects, or simply not wanting to inject forever — that is a completely reasonable question, and you deserve a straight answer rather than a scare or a sales pitch. So here is the honest picture, built entirely on published clinical trials.

The honest answer first

In plain terms: stopping usually means regaining a large share of what you lost, but not necessarily all of it. Many people still end up meaningfully lighter than when they started. Knowing that up front lets you plan for it instead of being blindsided.

What the withdrawal trials actually show

The best evidence comes from the extension of the STEP 1 trial — the large study that originally got semaglutide (Wegovy) approved for weight loss. Researchers followed nearly 2,000 adults for 68 weeks on the medication, then watched what happened for a full year after everyone stopped.

On treatment, participants lost an average of 17.3% of their body weight. In the year after stopping, they regained about 11.6 percentage points of it — roughly two-thirds of what they'd lost. A year off the drug, the average person was still 5.6% below their starting weight, and just under half (48%) had held onto at least a 5% loss. The researchers' own conclusion was blunt: this "confirms the chronicity of obesity" and suggests ongoing treatment is generally needed to keep the weight off (Wilding et al., Diabetes, Obesity and Metabolism, 2022).

Why the weight comes back — it's biology, not failure

This is the part that matters most emotionally, so we'll say it clearly: regaining weight after stopping is not a sign that you failed or that the medication "didn't really work." It's how the body is built to respond.

GLP-1 medications work partly by turning down appetite and hunger signals. When you stop, those signals come roaring back — often stronger than before — because your body treats weight loss as a threat and pushes to restore its previous set point. Appetite rises, fullness fades faster, and the same eating that maintained your loss on the drug now leads to regain. That's why researchers describe obesity as a chronic condition: much like blood pressure or blood sugar, it tends to drift back once the treatment that was controlling it is removed. Understanding how GLP-1 medications work makes this predictable rather than mysterious.

The strategy with the best evidence: a maintenance dose

If your real goal is keeping the weight off, the approach backed by the strongest data isn't a clever way of quitting — it's not fully quitting. A separate trial (STEP 4) tested exactly this. After 20 weeks of losing weight on semaglutide, people were split into two groups: keep taking it, or switch to a placebo.

• Those who continued the medication lost a further 7.9% of body weight over the next 48 weeks.
• Those switched to placebo regained about 6.9% over the same period.

That's the clearest signal we have: staying on the medication, often at a lower "maintenance" dose your clinician sets, is the most reliable way to hold results (Rubino et al., JAMA, 2021). For many people the honest reframe is that a GLP-1 is less like a short course of antibiotics and more like a long-term medication for a chronic condition.

Tapering versus stopping cold turkey

Here we have to be honest about the limits of the evidence: the big trials had people stop abruptly, so there isn't strong head-to-head proof that slowly tapering the dose prevents regain. What we can say is more modest and practical:

• Many clinicians prefer stepping the dose down gradually rather than stopping all at once, so they can watch how your appetite and weight respond and adjust before regain gathers momentum.
• A gradual step-down also gives you time to lock in the habits — eating patterns, activity, sleep — that have to carry more of the load once the medication is gone.
• Tapering is a decision to make with your prescriber, not on your own, because the right pace depends on your dose, your reasons for stopping, and your health history.

Protect your muscle on the way down

One reason regain is so easy is that rapid weight loss costs you some muscle along with fat, and less muscle means a slower metabolism. Holding onto muscle is one of the few levers genuinely in your control as you reduce or stop the medication. The two foundations are well established:

• Keep protein high. Prioritizing protein at every meal helps preserve muscle while you're losing or maintaining. Our GLP-1 nutrition guide covers how much and from where.
• Do resistance training. Strength work is the strongest signal to your body to keep muscle rather than break it down for energy. See our movement guide and GLP-1 and exercise for realistic starting points.

These aren't just "eat right and exercise" platitudes — on a GLP-1 taper they're the specific tools that protect the metabolism you'll be relying on afterward.

A realistic off-ramp checklist

• Decide with your clinician, not because of a bad week. Cost, side effects, and pregnancy plans are all valid reasons — talk them through rather than stopping abruptly.
• Ask about a maintenance dose first. Given the evidence, staying on a lower dose may achieve your goal better than stopping entirely.
• Have your habits in place before you taper, not after — protein, strength training, sleep, and a way to track your weight.
• Expect some regain and set a re-check point. Agree with your provider on a weight or timeframe at which you'd revisit the plan.
• Don't treat regain as failure. It's a known, biological response — and a reason to adjust the plan, not to give up.

When to talk to your clinician

Any change to how you take a GLP-1 — lowering the dose, pausing, or stopping — is a conversation to have with the provider who prescribed it. They can tailor the timing to your situation, watch for regain early, and help you decide whether a maintenance dose makes more sense than stopping. If you're weighing this because of cost, it's also worth checking whether a different program or dose could make staying on treatment more affordable before you decide to come off.

References

1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470 · doi:10.1111/dom.14725
2. Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414-1425. PMID: 33755728 · doi:10.1001/jama.2021.3224
3. NIH / NIDDK — Prescription Medications to Treat Overweight & Obesity
4. Mayo Clinic — Semaglutide (subcutaneous route) Description and Precautions
5. U.S. FDA — Drug Safety and Availability